Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 1.8% Higher – Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price was up 1.8% during trading on Wednesday . The stock traded as high as $0.24 and last traded at $0.23. Approximately 22,176,383 shares changed hands during trading, a decline of 65% from the average daily volume of 62,975,301 shares. The stock had previously closed at $0.23.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Thursday, January 9th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Down 1.4 %

The stock’s 50-day moving average is $0.25 and its 200-day moving average is $0.31. The stock has a market cap of $41.86 million, a P/E ratio of 0.00 and a beta of 2.02. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.